ABSTRACT
Atherosclerosis is the pathological basis of a variety of cardiovascular and cerebrovascular diseases. Its complicated etiology and chronic course seriously threaten human health. The prevention and treatment of atherosclerosis have been the focus of traditional Chinese and western medicine. This paper reviews the pathogenesis characteristics of atherosclerosis, and holds that deficiency of vital qi is the pathogenesis basis of atherosclerosis, which involves deficiency of heart, spleen and kidney, mutual knot of phlegm and blood stasis, and obstruction of veins. In clinical treatment, the common treatment were summarized on the principle of "replenishing deficiency and removing phlegm and blood stasis". In order to understand the relationship between deficiency and phlegm and blood stasis and atherosclerosis from the perspective of Traditional Chinese Medicine. The paper provides a theoretical basis for Traditional Chinese Medicine prevention and treatment for atherosclerosis.
ABSTRACT
Objective To observe the clinical effect and safety of Wenxin formula in the treatment of stable coronary heart disease angina patients with Syndrome of Yang deficiency with stagnation of the Blood and retention of Phlegm (SYBP). Methods A total of 65 stable coronary heart disease angina patients with SYBP were randomly assigned to the trial group and the control group (34 in the trial group and 31 in the control group). The trial group was treated with Wenxin formula, while the control group was treated with atorvastatin. The treatment lasted 4 weeks. The therapeutic effects on angina, reduction of Nitroglycerin, changes of electrocardiogram (ECG) and TCM syndrome score were observed before and after treatment.ResultsAfter treatment, the trial group had a similar effect with the control group in the aspects of the therapeutic effects on angina, reduction of Nitroglycerin and the ECG change. There was no statistical difference between the two groups (P>0.05). The changes of TCM syndrome score in the trial group was superior to the control group (P<0.05). The total effective rates of the trial group and the control group were 88.2% and 74.2%. The significant efficiency of the treatment group (29.41%) was significantly superior to the control group (9.68%) (P<0.05). No adverse reaction occurred during the therapeutic course.Conclusions The Wenxin formula was safe and effective in the treatment of stable coronary heart disease angina patients with SYBP.